BGI Touts Eventual Merck Deal

Beijing Genomics and Merck intend to collaborate, using BGI resources primarily to analyze genomic and epigenetic data off of Merck samples. The announcement was more than just a shot across the bow signaling BGI's intent to dominate the gene sequencing services world. It could eventually extend into the clinical arena, which could open up another whole new collaborative - and competitive - area with the West.

With Peter Kim, PhD, the president and EVP of Merck & Co. Inc.'s Merck Research Laboratories in attendance, in mid-September BGI (formerly the Beijing Genomics Institute) announced the signing of a statement of intent to form a working relationship with Merck. The organizations aim to utilize BGI's high-throughput DNA sequencing and analysis capabilities as the underpinning of a research collaboration, primarily to analyze genomic and epigenetic data generated using Merck samples.

The announcement was more than just a shot across the bow signaling publicly BGI's intentions to dominate the gene sequencing...

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.